Company intelligence / Profile preview
Senya Therapeutics
Bicester, Oxon, United Kingdomsenyatx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has developed a lead molecule, STX-002, that inhibits the activity of LRG1 and has successfully demonstrated its efficacy in a range of translational preclinical models. These results have shown that the compound is safe and well-tolerated.
- Therapeutic areas
- NephrologyOncologyEndocrinologyImmunologyCardiovascularOphthalmologyNeurology
- Modalities
- Biologics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Senya Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Senya Therapeutics.